Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Columbus, OH
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Toledo, OH
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Toledo, OH
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bethlehem, PA
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Houston, TX
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Roanoke, VA
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Marshfield, WI
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Marshfield, WI
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Westmead,
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Westmead,
Click here to add this to my saved trials
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
La Jolla, CA
A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza
A Phase III International, Randomized, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of 300 mg or 600 mg of Intravenous Zanamivir Twice Daily Compared to 75 mg of Oral Oseltamivir Twice Daily in the Treatment of Hospitalized Adults and Adolescents With Influenza
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
A Phase II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents
Status: Enrolling
Updated:  12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Nursing Home Residents
Status: Enrolling
Updated: 12/31/1969
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
Stanford Medical Center
mi
from
Stanford, CA
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
Stanford Medical Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
National Jewish Health
mi
from
Denver, CO
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
St. Michael's Hospital
mi
from
Toronto,
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
St. Michael's Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated:  12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Cross-sectional Characterization of Idiopathic Bronchiectasis
Cross-Sectional Characterization of Idiopathic Bronchiectasis
Status: Enrolling
Updated: 12/31/1969
Washington University in St. Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin
Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin
Quality of Life Study for Pediatric and Adult Patients Undergoing Hyperthermic Peritoneal Perfusion With Cisplatin
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma
A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Clearwater, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Honolulu, HI
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bardstown, KY
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bardstown, KY
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Albuquerque, NM
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New York, NY
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
New Bern, NC
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
New Bern, NC
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Portland, OR
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Carnegie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Carnegie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Erie, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Pleasant Hills, PA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Pleasant Hills, PA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Westmead,
Gynaecological Follow-up of a Subset of 580299/008 (NCT 00122681) Study Subjects
Gynaecological Follow-up of a Subset of 580299/008 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Westmead,
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Wenatchee, WA
Click here to add this to my saved trials
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Edmonton,
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Edmonton,
Click here to add this to my saved trials
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
Assessment of Alterations in Immune Function During Pregnancy and Post Parturition
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
mi
from
Birmingham, AL
Click here to add this to my saved trials
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Arkansas Children's Hospital
mi
from
Little Rock, AR
Click here to add this to my saved trials
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated:  12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia
A Randomized Open-Label Trial of Caspofungin Versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Status: Enrolling
Updated: 12/31/1969
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials